THDB(SH:600867)2017-04-11 16:00Financial Performance - The company achieved a net profit attributable to shareholders of RMB 640,923,429.97 in 2016, representing a 30.02% increase compared to RMB 492,958,977.12 in 2015[4]. - Total operating revenue for 2016 was RMB 2,040,394,539.90, up 22.23% from RMB 1,669,312,448.81 in 2015[23]. - The net cash flow from operating activities increased by 146.37% to RMB 725,763,119.95 in 2016, compared to RMB 294,578,586.76 in 2015[23]. - The company's total assets reached RMB 4,675,008,486.91 at the end of 2016, a 23.41% increase from RMB 3,788,129,812.91 in 2015[23]. - The net assets attributable to shareholders increased by 60.18% to RMB 3,939,219,528.22 at the end of 2016, compared to RMB 2,459,316,917.75 in 2015[23]. - Basic earnings per share for 2016 were RMB 0.46, a 6.98% increase from RMB 0.43 in 2015[24]. - The total profit for 2016 was CNY 758.93 million, reflecting a growth of 33.03% compared to the previous year[49]. - The company's operating costs rose to CNY 491,852,600.31, an increase of 19.11% from the previous year[88]. - The gross profit margin for biological products was 87.79%, reflecting an increase of 2.23 percentage points compared to the previous year[93]. - The company reported a total revenue of approximately CNY 1.2 billion from the 30/70 mixed recombinant human insulin injection, with a sales volume of 2,990.67 million units[126]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2 per 10 shares and issue 2 bonus shares for every 10 shares held, totaling a distribution of RMB 568,773,392.20[4]. - The dividend payout ratio for 2016 was 44.37% of the net profit attributable to ordinary shareholders, compared to 46.08% in 2015 and 73.64% in 2014[166]. - The company strictly adhered to its dividend policy, ensuring transparency and protection of minority shareholders' rights during the decision-making process[165]. - The company distributed a cash dividend of 2 RMB per 10 shares and issued 2 bonus shares for every 10 shares held, resulting in a total of 227,166,220 shares being distributed as stock dividends[191]. Research and Development - The company is actively involved in the development of new products and technologies, particularly in the biopharmaceutical sector, which is seen as a high-potential area for growth[39]. - The total R&D investment for the reporting period was CNY 87,322,472.44, accounting for 4.28% of the operating revenue[104]. - The number of R&D personnel is 284, representing 13.56% of the total workforce[104]. - The company has initiated the development of four categories of insulin analogs, aiming to solidify its leading position in the insulin production sector[129]. - The company is focusing on the development of insulin analogs and oral hypoglycemic agents, which will enhance its product line and market competitiveness[129]. - The company has completed Phase III clinical research for Aspart Insulin 30 Injection, with most participating hospitals' ethical reviews approved and currently in contract negotiation phase[57]. - The company has made progress in the development of GLP-1 analogs, with clinical research for Liraglutide and Dulaglutide ongoing, aiming to enhance product quality standards[60][61][62]. Market Position and Strategy - The company achieved a market share of over 20% in the human insulin market, ranking second after foreign enterprises, which previously held a 99.9% market share[40]. - The pharmaceutical industry is expected to grow steadily due to aging population and urbanization, despite recent regulatory challenges and price reductions[35]. - The company aims to break the monopoly of insulin analogs in the market, providing diverse medication options and reducing costs for patients[136]. - The company is focused on expanding its product portfolio in the diabetes treatment sector, which is currently dominated by foreign enterprises[139]. - The company has established a strong brand presence in the diabetes sector, competing effectively with multinational pharmaceutical companies[141]. Environmental and Social Responsibility - The company processed nearly 150,000 tons of wastewater in 2016, with key pollutants' discharge indicators below national standards, such as CODcr average value of 26 mg/L and BOD5 average value of 5.6 mg/L[184]. - The company achieved a desulfurization rate improvement from 30% to over 90% by installing a new 30 tons/hour desulfurization system, significantly reducing sulfur dioxide emissions by 388 tons annually[186]. - The company actively fulfills social responsibilities, focusing on resource conservation and environmental protection while creating value for stakeholders[182]. - The company has received environmental approval for new projects, including the production base for insulin analogs and traditional Chinese medicine extraction workshops[185]. Corporate Governance and Compliance - The company has no major litigation or arbitration matters during the year[174]. - The company has no outstanding court judgments or significant debts due as of the reporting period[174]. - The company maintained a commitment to avoid related party transactions unless necessary, adhering to fair pricing principles[167]. - The company has no significant changes in its major shareholders or actual controllers' integrity status[174]. - The company has implemented an employee stock option and restricted stock incentive plan, which was approved by the board in May 2014[175].